MARKET

XCUR

XCUR

Exicure Inc
NASDAQ
4.473
+0.058
+1.31%
After Hours: 4.470 -0.003 -0.07% 18:24 03/30 EDT
OPEN
4.420
PREV CLOSE
4.415
HIGH
4.511
LOW
4.250
VOLUME
15.13K
TURNOVER
--
52 WEEK HIGH
14.11
52 WEEK LOW
3.101
MARKET CAP
28.51M
P/E (TTM)
-1.4580
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XCUR last week (0323-0327)?
Weekly Report · 21h ago
Exicure Announces Routine Board and Audit Committee Change
TipRanks · 3d ago
Exicure board changes; Sangjin Yeo resigns from board and audit committee effective March 27, 2026
Reuters · 3d ago
Exicure GAAP EPS of -$0.79
Seeking Alpha · 4d ago
Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.
Benzinga · 5d ago
Exicure FY2025 net loss narrows to $4.9 million; cash and cash equivalents drop 70.05% to $3.7 million
Reuters · 5d ago
EXICURE, INC. REPORTS FULL YEAR 2025 FINANCIAL RESULTS
Reuters · 5d ago
Press Release: Exicure, Inc. Reports Full Year 2025 Financial Results
Dow Jones · 5d ago
More
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Webull offers Exicure Inc stock information, including NASDAQ: XCUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XCUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform.